Putative biological mechanisms of efficiency of substrate reduction therapies for mucopolysaccharidoses

Archivum Immunologiae et Therapiae Experimentalis

Volumn 60, Issue 6, 2012, Pages 461-468

  Banecka Majkutewicz, Zyta ^a   Jakóbkiewicz Banecka, Joanna ^b   Gabig Cimińska, Magdalena ^b   Wegrzyn, Alicja ^c   Węgrzyn, Grzegorz ^b  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

^b UNIVERSITY OF GDA SK   (Poland)

^c UNIVERSITY OF SZCZECIN   (Poland)

Author keywords

Gene expression targeted isoflavone therapy; Genistein; Glycosaminoglycans; Lysosomal storage diseases; Mucopolysaccharidoses; Substrate reduction therapy

Indexed keywords

GENISTEIN; GLYCOSAMINOGLYCAN; PLACEBO; RHODAMINE B; SMALL INTERFERING RNA;

BONE MARROW TRANSPLANTATION; CARBOHYDRATE SYNTHESIS; CELL LEVEL; CLINICAL TRIAL (TOPIC); CONTROLLED CLINICAL TRIAL (TOPIC); DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; ENZYME DEGRADATION; ENZYME SUBSTRATE; EXPERIMENTAL ANIMAL; GALT1 GENE; GALT2 GENE; GENE; GENE EXPRESSION; GENE SILENCING; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IN VITRO STUDY; LOW DRUG DOSE; MUCOPOLYSACCHARIDOSIS; NONHUMAN; NONVIRAL GENE THERAPY; REVIEW; RNA INTERFERENCE; SANFILIPPO SYNDROME; STOP CODON; SUBSTRATE REDUCTION THERAPY; THERAPY; XYLT1 GENE; XYLT2 GENE;

EID: 84872107505     PISSN: 0004069X     EISSN: 16614917     Source Type: Journal    
DOI: 10.1007/s00005-012-0195-9     Document Type: Review

References (50)

1. Anson DS, McIntyre C, Byers S (2011) Therapies for neurological disease in the mucopolysaccharidoses. Curr Gene Ther 11:132-143
2. Arfi A, Richard M, Gandolphe C, Scherman D (2010) Storage correction in cells of patients suffering from mucopolysaccharidoses types IIIA and VII after treatment with genistein and other isoflavones. J Inherit Metab Dis 33:61-67
3. Beck M (2010) Therapy for lysosomal storage disorders. IUBMB Life 62:33-40
4. Benson PF, Dean MF, Muir H (1972) A form of mucopolysaccharidosis with visceral storage and excessive urinary excretion of chondroitin sulphate. Dev Med Child Neurol 14:69-74
5. Cain H, Egner E, Kresse H (1977) Mucopolysaccharidosis III A (Sanfilippo disease type A). Histochemical, electron microscopical and biochemical findings. Beitr Pathol 160:58-72
6. Clarke LA (2008) Idursulfase for the treatment of mucopolysaccharidosis II. Expert Opin Pharmacother 9:311-317
7. Cotrim AP, Baum BJ (2008) Gene therapy: some history, applications, problems, and prospects. Toxicol Pathol 36:97-103
8. de Ru MH, Boelens JJ, Das AM, Jones SA, van der Lee JH, Mahlaoui N, Mengel E, Offringa M, O'Meara A, Parini R, Rovelli A, Sykora KW, Valayannopoulos V, Vellodi A, Wynn RF, Wijburg FA (2011) Enzyme replacement therapy and/or hematopoietic stem cell transplantation at diagnosis in patients with mucopolysaccharidosis type I: results of a European consensus procedure. Orphanet J Rare Dis 6:55
9. de Ruijter JVM, Valstar MJ, Narajczyk M, Wegrzyn G, Kulik W, Ijlst L, Wagemans T, van der Wal WM, Wijburg FA (2012) Genistein in Sanfilippo disease: a randomized controlled crossover trial. Ann Neurol 71:110-120
10. Delgadillo V, O'Callaghan Mdel M, Artuch R, Montero R, Pineda M (2011) Genistein supplementation in patients affected by Sanfilippo disease. J Inherit Metab Dis 34:1039-1044
11. Dorfman A (1964) Metabolism of acid mucopolysaccharides. Biophys J 4(Suppl 1):155-165
12. Dziedzic D, Wegrzyn G, Jakobkiewicz-Banecka J (2010) Impairment of glycosaminoglycan synthesis in mucopolysaccharidosis type IIIA cells by using siRNA: a potential therapeutic approach for Sanfilippo disease. Eur J Hum Genet 18:200-205
13. Elstein D, Hollak C, Aerts JM, van Weely S, Maas M, Cox TM, Lachmann RH, Hrebicek M, Platt FM, Butters TD, Dwek RA, Zimran A (2004) Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease. J Inherit Metab Dis 27:757-766
14. Friso A, Tomanin R, Salvalaio M, Scarpa M (2010) Genistein reduces glycosaminoglycan levels in a mouse model of mucopolysaccharidosis type II. Br J Pharmacol 159:1082-1091
15. Fux L, Ilan N, Sanderson RD, Vlodavsky I (2009) Heparanase: busy at the cell surface. Trends Biochem Sci 34:511-519
16. Jakobkiewicz-Banecka J, Wegrzyn A, Wegrzyn G (2007) Substrate deprivation therapy: a new hope for patients suffering from neuronopathic forms of inherited lysosomal storage diseases. J Appl Genet 48:383-388
17. Jakobkiewicz-Banecka J, Piotrowska E, Narajczyk M, Baranska S, Wegrzyn G (2009) Genistein-mediated inhibition of glycosaminoglycan synthesis, which corrects storage in cells of patients suffering from mucopolysaccharidoses, acts by influencing an epidermal growth factor-dependent pathway. J Biomed Sci 16:26
18. Jakobkiewicz-Banecka J, Piotrowska E, Gabig-Ciminska M et al (2011) Substrate reduction therapies for mucopolysaccharidoses. Curr Pharm Biotechnol 12:1860-1865
19. Kaidonis X, Liaw WC, Roberts AD, Ly M, Anson D, Byers S (2010) Gene silencing of EXTL2 and EXTL3 as a substrate deprivation therapy for heparan sulphate storing mucopolysaccharidoses. Eur J Hum Genet 18:194-199
20. Kloska A, Bohdanowicz J, Konopa G et al (2005) Changes in hair morphology of mucopolysaccharidosis I patients treated with recombinant human alpha-L-iduronidase (laronidase, Aldurazyme). Am J Med Genet A 139:199-203
21. Kloska A, Jakobkiewicz-Banecka J, Narajczyk M, Banecka-Majkutewicz Z, Wegrzyn G (2011) Effects of flavonoids on glycosaminoglycan synthesis: implications for substrate reduction therapy in Sanfilippo disease and other mucopolysaccharidoses. Metab Brain Dis 26:1-8
22. Lau AA, Hannouche H, Rozaklis T, Hassiotis S, Hopwood JJ, Hemsley KM (2010) Allogeneic stem cell transplantation does not improve neurological deficits in mucopolysaccharidosis type IIIA mice. Exp Neurol 225:445-454
23. Machaczka M, Hast R, Dahlman I, Lerner R, Klimkowska M, Engvall M, Hägglund H (2012) Substrate reduction therapy with miglustat for type 1 Gaucher disease: a retrospective analysis from a single institution. Ups J Med Sci 117:28-34
24. Malinova V, Wegrzyn G, Narajczyk M (2012) The use of elevated doses of genistein-rich soy extract in the gene expressiontargeted isoflavone therapy (GET IT) for Sanfilippo disease patients. JIMD Rep 5:21-25
25. Malinowska M, Jakobkiewicz-Banecka J, Kloska A et al (2008) Abnormalities in the hair morphology of patients with some but not all types of mucopolysaccharidoses. Eur J Pediatr 167:203-209
26. Malinowska M, Wilkinson FL, Bennett W et al (2009) Genistein reduces lysosomal storage in peripheral tissues of mucopolysaccharide IIIB mice. Mol Genet Metab 98:235-242
27. Malinowska M, Wilkinson FL, Langford-Smith KJ et al (2010) Genistein improves neuropathology and corrects behaviour in a mouse model of neurodegenerative metabolic disease. PLoS ONE 5:e14192
28. Marucha J, Tylki-Szymanska A, Jakobkiewicz-Banecka J et al (2011) Improvement in the range of joint motion in seven patients with mucopolysaccharidosis type II during experimental gene expression- targeted isoflavone therapy (GET IT). Am J Med Genet A 155:2257-2262
29. Munoz-Rojas MV, Vieira T, Costa R, Fagondes S, John A, Jardim LB, Vedolin LM, Raymundo M, Dickson PI, Kakkis E, Giugliani R (2008) Intrathecal enzyme replacement therapy in a patient with mucopolysaccharidosis type I and symptomatic spinal cord compression. Am J Med Genet A 146:2538-2544
30. Munoz-Rojas MV, Horovitz DD, Jardim LB, Raymundo M, Llerena JC Jr, de Magalhães Tde S, Vieira TA, Costa R, Kakkis E, Giugliani R (2010) Intrathecal administration of recombinant human N-acetylgalactosamine 4-sulfatase to a MPS VI patient with pachymeningitis cervicalis. Mol Genet Metab 99:346-350
31. Neufeld EF, Muenzer J (2001) The mucopolysaccharidoses. In: Scriver CR et al (eds) The metabolic and molecular bases of inherited disease, vol III. McGraw-Hill, New York, pp 3421-3452
32. Pastores GM, Barnett NL, Kolodny EH (2005) An open-label, noncomparative study of miglustat in type I Gaucher disease: efficacy and tolerability over 24 months of treatment. Clin Ther 27:1215-1227
33. Patterson MC, Vecchio D, Prady H, Abel L, Wraith JE (2007) Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study. Lancet Neurol 6:765-772
34. Piotrowska E, Jakobkiewicz-Banecka J, Baranska S et al (2006) Genistein-mediated inhibition of glycosaminoglycan synthesis as a basis for gene expression-targeted isoflavone therapy for mucopolysaccharidoses. Eur J Hum Genet 14:846-852
35. Piotrowska E, Jakóbkiewicz-Banecka J, Tylki-Szymańska A et al (2008) The use of genistin-rich isoflavone extract in substrate reduction therapy for Sanfilippo disease: open-label, pilot study in 10 pediatric patients. Curr Ther Res 69:166-179
36. Piotrowska E, Jakobkiewicz-Banecka J, Wegrzyn G (2010) Different amounts of isoflavones in various commercially available soy extracts in the light of gene expression-targeted isoflavone therapy. Phytother Res 24(Suppl 1):S109-S113
37. Piotrowska E, Jakobkiewicz-Banecka J, Maryniak A et al (2011) Two-year follow-up of Sanfilippo Disease patients treated with a genistein-rich isoflavone extract: assessment of effects on cognitive functions and general status of patients. Med Sci Monit 17:CR196-CR202
38. Ponder KP (2008) Immune response hinders therapy for lysosomal storage diseases. J Clin Invest 118:2686-2689
39. Prasad VK, Kurtzberg J (2010) Transplant outcomes in mucopolysaccharidoses. Semin Hematol 47:59-69
40. Roberts AL, Thomas BJ, Wilkinson AS, Fletcher JM, Byers S (2006) Inhibition of glycosaminoglycan synthesis using rhodamine B in a mouse model of mucopolysaccharidosis type IIIA. Pediatr Res 60:309-314
41. Roberts AL, Rees MH, Klebe S, Fletcher JM, Byers S (2007) Improvement in behaviour after substrate deprivation therapy with rhodamine B in a mouse model of MPS IIIA. Mol Genet Metab 92:115-121
42. Schultz ML, Tecedor L, Chang M, Davidson BL (2011) Clarifying lysosomal storage diseases. Trends Neurosci 34:401-410
43. Tylki-Szymańska A, Groener JE, Kamiński ML, Ługowska A, Jurkiewicz E, Czartoryska B (2011) Gaucher disease due to saposin C deficiency, previously described as non-neuronopathic form - no positive effects after 2-years of miglustat therapy. Mol Genet Metab 104:627-630
44. Van Gemund JJ, Daems WT, Vio PA, Giesberts MA (1971) Electron microscopy of intestinal suction-biopsy specimens as an aid in the diagnosis of mucopolysaccharidoses and other lysosomal storage diseases. Maandschr Kindergeneeskd 39:211-217
45. Wegrzyn A (2012) Gene expression-targeted isoflavone therapy. IUBMB Life 64:307-315
46. Wegrzyn G, Wegrzyn A, Tylki-Szymanska A (2004) A general model for genetic regulation of turnover of glycosaminoglycans suggests a possible procedure for prediction of severity and clinical progress of mucopolysaccharidoses. Med Hypotheses 62:986-992
47. Wegrzyn G, Tylki-Szymanska A, Liberek A et al (2007) Rapid deterioration of a patient with mucopolysaccharidosis type I during interruption of enzyme replacement therapy. Am J Med Genet A 143:1925-1927
48. WegrzynG, Jakobkiewicz-Banecka J,NarajczykMet al (2010)Why are behaviors of children suffering fromvarious neuronopathic types of mucopolysaccharidoses different? Med Hypotheses 75:605-609
49. Weinreb NJ, Barranger JA, Charrow J, Grabowski GA, Mankin HJ, Mistry P (2005) Guidance on the use of miglustat for treating patients with type 1 Gaucher disease. Am J Hematol 80:223-229
50. Wraith JE (2008) Enzyme replacement therapy with idursulfase in patients with mucopolysaccharidosis type II. Acta Paediatr Suppl 97:76-78